ESMO 2019 | irAEs with single-agent PD-1 vs PD-L1 inhibitors

Petros Grivas

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, elaborates on the immune-related adverse events (irAEs) with single-agent PD-1 vs. PD-L1 inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video